I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Helmy Eltoukhy Biography and Net Worth

CEO of Guardant Health

Helmy Eltoukhy, Ph.D. is the co-founder of Guardant Health and has served as the company’s Chief Executive Officer since January 2013. Prior to founding Guardant, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007, he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008. He joined the Stanford Genome Technology Center, or SGTC, as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.

What is Helmy Eltoukhy's net worth?: The estimated net worth of Helmy Eltoukhy is at least $61.91 million as of March 15th, 2023. Dr. Eltoukhy owns 2,049,238 shares of Guardant Health stock worth more than $61,907,480 as of November 14th. This net worth approximation does not reflect any other investments that Dr. Eltoukhy may own. Additionally, Dr. Eltoukhy receives an annual salary of $11,630.00 as CEO at Guardant Health. Learn More about Helmy Eltoukhy's net worth.
How old is Helmy Eltoukhy?: Dr. Eltoukhy is currently 44 years old. There are 6 older executives and no younger executives at Guardant Health. The oldest executive at Guardant Health is Mr. Kumud Kalia, Chief Information Officer, who is 58 years old. Learn More on Helmy Eltoukhy's age.
What is Helmy Eltoukhy's salary?: As the CEO of Guardant Health, Inc., Dr. Eltoukhy earns $11,630.00 per year. There are 4 executives that earn more than Dr. Eltoukhy. The highest earning executive at Guardant Health is Dr. Craig Eagle M.D., Chief Medical Officer, who commands a salary of $649,130.00 per year. Learn More on Helmy Eltoukhy's salary.
How do I contact Helmy Eltoukhy?: The corporate mailing address for Dr. Eltoukhy and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Helmy Eltoukhy's contact information.
Has Helmy Eltoukhy been buying or selling shares of Guardant Health?: Helmy Eltoukhy has not been actively trading shares of Guardant Health during the last ninety days. Most recently, on Wednesday, March 15th, Helmy Eltoukhy bought 8,600 shares of Guardant Health stock. The stock was acquired at an average cost of $26.15 per share, with a total value of $224,890.00. Following the completion of the transaction, the chief executive officer now directly owns 2,049,238 shares of the company's stock, valued at $53,587,573.70. Learn More on Helmy Eltoukhy's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), and Amirali Talasaz (COO). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, Guardant Health insiders bought shares 1 times. They purchased a total of 2,187 shares worth more than $38,972.34. During the last year, insiders at the sold shares 5 times. They sold a total of 8,996 shares worth more than $246,862.40. The most recent insider tranaction occured on November, 13th when Director Meghan V Joyce sold 2,896 shares worth more than $86,590.40. Insiders at Guardant Health own 5.5% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 11/13/2024.

Helmy Eltoukhy Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2023	Buy	8,600	$26.15	$224,890.00	2,049,238
11/23/2021	Buy	54,500	$94.36	$5,142,620.00
11/19/2021	Buy	50,000	$98.12	$4,906,000.00
4/26/2021	Sell	751	$160.01	$120,167.51	1,828,514
4/23/2021	Sell	7,388	$160.12	$1,182,966.56	1,828,514
4/21/2021	Sell	56,358	$151.76	$8,552,890.08	1,906,556
4/19/2021	Sell	50,932	$152.97	$7,791,068.04	2,161,187
4/16/2021	Sell	51,123	$158.34	$8,094,815.82	2,161,187
4/14/2021	Sell	60,982	$156.54	$9,546,122.28	2,405,525
4/12/2021	Sell	72,861	$154.59	$11,263,581.99	2,405,525
4/9/2021	Sell	60,996	$156.86	$9,567,832.56	2,624,751
4/7/2021	Sell	36,843	$158.61	$5,843,668.23	2,624,751
1/25/2021	Sell	58,811	$157.26	$9,248,617.86	2,781,007
1/21/2021	Sell	173,206	$162.01	$28,061,104.06	3,103,275
1/19/2021	Sell	103,717	$160.12	$16,607,166.04	3,103,275
1/15/2021	Sell	150,000	$158.39	$23,758,500.00	3,129,518
9/18/2020	Sell	65,422	$102.09	$6,678,931.98	2,884,952
9/16/2020	Sell	218,509	$103.92	$22,707,455.28	3,317,456
4/16/2020	Sell	200	$70.01	$14,002.00	3,191,084
4/14/2020	Sell	2,701	$70.06	$189,232.06	3,191,084
3/30/2020	Sell	178,093	$69.83	$12,436,234.19	3,472,181
8/16/2019	Sell	253,699	$100.21	$25,423,176.79
8/13/2019	Sell	426,301	$99.58	$42,451,053.58
5/14/2019	Sell	78,660	$72.34	$5,690,264.40
5/1/2019	Sell	131,340	$65.32	$8,579,128.80
4/22/2019	Sell	90,000	$65.28	$5,875,200.00

Helmy Eltoukhy Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $30.21

$30.03

$31.32

50 Day Range

MA: $23.57

$20.20

$31.61

2 Week Range

Now: $30.21

$15.81

$37.04

Volume

2,020,772 shs

Average Volume

2,071,955 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Helmy Eltoukhy Biography and Net Worth

What is Helmy Eltoukhy's net worth?

How old is Helmy Eltoukhy?

What is Helmy Eltoukhy's salary?

How do I contact Helmy Eltoukhy?

Has Helmy Eltoukhy been buying or selling shares of Guardant Health?

Who are Guardant Health's active insiders?

Are insiders buying or selling shares of Guardant Health?